{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:40:42Z","timestamp":1770237642359,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1063144"],"award-info":[{"award-number":["NRF-2022R1F1A1063144"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-024-01471-3","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:50:26Z","timestamp":1736869826000},"page":"285-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of Telmisartan in Healthy Subjects and Hypertensive Patients"],"prefix":"10.1007","volume":"64","author":[{"given":"In Hwan","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooyoon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-8564","authenticated-orcid":false,"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-9376","authenticated-orcid":false,"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-0565","authenticated-orcid":false,"given":"In-hwan","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"17","key":"1471_CR1","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1517\/14656566.2011.632367","volume":"12","author":"M Destro","year":"2011","unstructured":"Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother. 2011;12(17):2719\u201335. https:\/\/doi.org\/10.1517\/14656566.2011.632367.","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"1471_CR2","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2165\/00003495-200868130-00010","volume":"68","author":"GL Plosker","year":"2008","unstructured":"Plosker GL, White WB. Telmisartan\/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs. 2008;68(13):1877\u201399. https:\/\/doi.org\/10.2165\/00003495-200868130-00010.","journal-title":"Drugs"},{"issue":"15","key":"1471_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","volume":"66","author":"AJ Battershill","year":"2006","unstructured":"Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66(15):51\u201383. https:\/\/doi.org\/10.2165\/00003495-200666010-00004.","journal-title":"Drugs"},{"key":"1471_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116169","volume":"171","author":"M Imenshahidi","year":"2024","unstructured":"Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171: 116169. https:\/\/doi.org\/10.1016\/j.biopha.2024.116169.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1471_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1083","volume":"11","author":"RP Rothlin","year":"2023","unstructured":"Rothlin RP, Pelorosso FG, Duarte M, Nicolosi L, Ignacio FC, Salgado MV, et al. Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacol Res Perspect. 2023;11(2): e01083. https:\/\/doi.org\/10.1002\/prp2.1083.","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"1471_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/17425255.2010.494597","volume":"6","author":"S Deppe","year":"2010","unstructured":"Deppe S, B\u00f6ger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6(7):863\u201371. https:\/\/doi.org\/10.1517\/17425255.2010.494597.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1471_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11094-019-02062-4","volume":"53","author":"D Romodanovskii","year":"2019","unstructured":"Romodanovskii D, Goryachev D, Khokhlov A, Miroshnikov A. Investigation planning and bioequivalence evaluation of angiotensin II receptor antagonists. Pharm Chem J. 2019;53:680\u20134. https:\/\/doi.org\/10.1007\/s11094-019-02062-4.","journal-title":"Pharm Chem J"},{"issue":"4","key":"1471_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u201337. https:\/\/doi.org\/10.1038\/s41581-019-0244-2.","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"1471_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802. https:\/\/doi.org\/10.1038\/s41569-021-00559-8.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"1471_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2165\/00003088-200645050-00001","volume":"45","author":"P Fagiolino","year":"2006","unstructured":"Fagiolino P, Eiraldi R, V\u00e1zquez M. The influence of cardiovascular physiology on dose\/pharmacokinetic and pharmacokinetic\/pharmacodynamic relationships. Clin Pharmacokinet. 2006;45(5):433\u201348. https:\/\/doi.org\/10.2165\/00003088-200645050-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1471_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17425255.2019.1588249","volume":"15","author":"L Peeters","year":"2019","unstructured":"Peeters L, Kester M, Feyz L, Van Den Bemt P, Koch B, Van Gelder T, et al. Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension. Expert Opin Drug Metab Toxicol. 2019;15(4):287\u201397. https:\/\/doi.org\/10.1080\/17425255.2019.1588249.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"1471_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2125.1985.tb05072.x","volume":"20","author":"J Rigby","year":"1985","unstructured":"Rigby J, Scott A, Hawksworth G, Petrie J. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol. 1985;20(4):327\u201331. https:\/\/doi.org\/10.1111\/j.1365-2125.1985.tb05072.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1471_CR13","doi-asserted-by":"publisher","first-page":"10A","DOI":"10.1016\/0002-9149(94)90269-0","volume":"73","author":"DR Abernethy","year":"1994","unstructured":"Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol. 1994;73(3):10A-17A. https:\/\/doi.org\/10.1016\/0002-9149(94)90269-0.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1471_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.1983.tb02139.x","volume":"16","author":"P Meredith","year":"1983","unstructured":"Meredith P, Elliott H, McSharry D, Kelman A, Reid J. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol. 1983;16(1):27\u201332. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02139.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1471_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2165\/00003088-198814060-00004","volume":"14","author":"S Landahl","year":"1988","unstructured":"Landahl S, Edgar B, Gabrielsson M, Larsson M, Lernfelt B, Lundborg P, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients: a comparison with young healthy subjects. Clin Pharmacokinet. 1988;14(6):374\u201383. https:\/\/doi.org\/10.2165\/00003088-198814060-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1471_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00005344-200207000-00014","volume":"40","author":"MR Marino","year":"2002","unstructured":"Marino MR, Vachharajani NN. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol. 2002;40(1):112\u201322. https:\/\/doi.org\/10.1097\/00005344-200207000-00014.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"1471_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","volume":"6","author":"NH Holford","year":"1981","unstructured":"Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429\u201353. https:\/\/doi.org\/10.2165\/00003088-198106060-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1471_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"issue":"7414","key":"1471_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"7","key":"1471_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783\u201395. https:\/\/doi.org\/10.1007\/s40262-015-0236-8.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1471_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(6): e50. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"1471_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1471_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10928-010-9177-x","volume":"38","author":"PG Baverel","year":"2011","unstructured":"Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63\u201382. https:\/\/doi.org\/10.1007\/s10928-010-9177-x.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1471_CR24","first-page":"403","volume":"4","author":"K Madhusudhan","year":"2016","unstructured":"Madhusudhan K, Mahesh K, Balusu N, Kumar M, Savakula S, Reddy SSS, et al. Pharmacokinetic and bioequivalence com-parison between telmisartan tablets 80mg: an open label, balanced, randomized-sequence, single-dose, two-period cross-over study in healthy male volunteers. Int J Pharm Drug Anal. 2016;4(8):403\u201310.","journal-title":"Int J Pharm Drug Anal."},{"issue":"4","key":"1471_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/cpt.1928","volume":"108","author":"P Hirvensalo","year":"2020","unstructured":"Hirvensalo P, Tornio A, Launiainen T, Paile-Hyv\u00e4rinen M, Tapaninen T, Neuvonen M, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics\u2014a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 2020;108(4):885\u201395. https:\/\/doi.org\/10.1002\/cpt.1928.","journal-title":"Clin Pharmacol Ther"},{"issue":"12 Pt 1","key":"1471_CR26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/009127000004001203","volume":"40","author":"CL Young","year":"2000","unstructured":"Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol. 2000;40(12 Pt 1):1323\u201330. https:\/\/doi.org\/10.1177\/009127000004001203.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1471_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40261-016-0406-y","volume":"36","author":"SJ Seong","year":"2016","unstructured":"Seong SJ, Lim MS, Lee J, Ohk B, Gwon MR, Kim BK, et al. Evaluation of a pharmacokinetic interaction between telmisartan and chlorthalidone in healthy male adult subjects. Clin Drug Investig. 2016;36(8):613\u201323. https:\/\/doi.org\/10.1007\/s40261-016-0406-y.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1471_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s12325-020-01592-8","volume":"38","author":"CH Kim","year":"2021","unstructured":"Kim CH, Kang SI, Shin D. Pharmacokinetic interaction between telmisartan and rosuvastatin\/ezetimibe after multiple oral administration in healthy subjects. Adv Ther. 2021;38(2):1094\u2013105. https:\/\/doi.org\/10.1007\/s12325-020-01592-8.","journal-title":"Adv Ther"},{"issue":"11","key":"1471_CR29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cpdd.926","volume":"10","author":"KY Huh","year":"2021","unstructured":"Huh KY, Lee SW, Lee SB, Kim KT, Jang IJ, Lee S. Pharmacokinetic interaction among ezetimibe, rosuvastatin, and telmisartan. Clin Pharmacol Drug Dev. 2021;10(11):1290\u20136. https:\/\/doi.org\/10.1002\/cpdd.926.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"8","key":"1471_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.clinthera.2014.06.007","volume":"36","author":"M Son","year":"2014","unstructured":"Son M, Kim Y, Lee D, Roh H, Son H, Guk J, et al. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. Clin Ther. 2014;36(8):1147\u201358. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.007.","journal-title":"Clin Ther"},{"issue":"7","key":"1471_CR31","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.clinthera.2012.05.010","volume":"34","author":"YH Noh","year":"2012","unstructured":"Noh YH, Lim HS, Kim MJ, Kim YH, Choi HY, Sung HR, et al. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Clin Ther. 2012;34(7):1625\u201335. https:\/\/doi.org\/10.1016\/j.clinthera.2012.05.010.","journal-title":"Clin Ther"},{"issue":"12 Pt 1","key":"1471_CR32","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1177\/009127000004001202","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Schmid J, T\u00fcrck D, Switek H, Verhagen A, Peeters PA, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1312\u201322. https:\/\/doi.org\/10.1177\/009127000004001202.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1471_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1080\/03639045.2020.1820042","volume":"46","author":"AS Paramanindita","year":"2020","unstructured":"Paramanindita AS, Harahap Y, Prasaja B, Wijayanti TR, Lusthom W, Sofiah RE, et al. A bioequivalence study of two telmisartan 80 mg tablets in healthy Indonesian subjects: an open label, three-way, three-period, partial replicate crossover study. Drug Dev Ind Pharm. 2020;46(11):1747\u201352. https:\/\/doi.org\/10.1080\/03639045.2020.1820042.","journal-title":"Drug Dev Ind Pharm"},{"issue":"12 Pt 1","key":"1471_CR34","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1177\/009127000004001208","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Brickl R, Franke H. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1365\u201372. https:\/\/doi.org\/10.1177\/009127000004001208.","journal-title":"J Clin Pharmacol"},{"issue":"12 Pt 1","key":"1471_CR35","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1177\/009127000004001207","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Sch\u00f6ndorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 1):1355\u201364. https:\/\/doi.org\/10.1177\/009127000004001207.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1471_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/FPC.0b013e3283489ce2","volume":"21","author":"I Ieiri","year":"2011","unstructured":"Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genom. 2011;21(8):495\u2013505. https:\/\/doi.org\/10.1097\/FPC.0b013e3283489ce2.","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"1471_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1515\/CCLM.2009.019","volume":"47","author":"X Guo","year":"2009","unstructured":"Guo X, Chen XP, Cheng ZN, Luo X, Guo R, Chen L, et al. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med. 2009;47(1):38\u201343. https:\/\/doi.org\/10.1515\/CCLM.2009.019.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"1471_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1055\/s-0031-1296753","volume":"56","author":"P Zhang","year":"2006","unstructured":"Zhang P, Zhang Y, Chen X, Li R, Yin J, Zhong D. Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels. Arzneimittelforschung. 2006;56(8):569\u201373. https:\/\/doi.org\/10.1055\/s-0031-1296753.","journal-title":"Arzneimittelforschung"},{"issue":"12 Pt 1","key":"1471_CR39","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1177\/009127000004001210","volume":"40","author":"DH Smith","year":"2000","unstructured":"Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000;40(12 Pt 1):1380\u201390. https:\/\/doi.org\/10.1177\/009127000004001210.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1471_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0091270006297225","volume":"47","author":"M Bajcetic","year":"2007","unstructured":"Bajcetic M, Benndorf RA, Appel D, Schwedhelm E, Schulze F, Riekhof D, et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol. 2007;47(3):295\u2013304. https:\/\/doi.org\/10.1177\/0091270006297225.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1471_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/147323000002800401","volume":"28","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28(4):149\u201367. https:\/\/doi.org\/10.1177\/147323000002800401.","journal-title":"J Int Med Res"},{"issue":"7","key":"1471_CR42","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/psp4.13154","volume":"13","author":"T Tsuchitani","year":"2024","unstructured":"Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama Y. Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. CPT Pharmacomet Syst Pharmacol. 2024;13(7):1224\u201337. https:\/\/doi.org\/10.1002\/psp4.13154.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"1471_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2133\/dmpk.18.203","volume":"18","author":"S Tatami","year":"2003","unstructured":"Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet. 2003;18(3):203\u201311. https:\/\/doi.org\/10.2133\/dmpk.18.203.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"1471_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2133\/dmpk.19.15","volume":"19","author":"S Tatami","year":"2004","unstructured":"Tatami S, Yamamura N, Sarashina A, Yong CL, Igarashi T, Tanigawara Y. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet. 2004;19(1):15\u201323. https:\/\/doi.org\/10.2133\/dmpk.19.15.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"07","key":"1471_CR45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/s-0033-1341424","volume":"63","author":"IH Baek","year":"2013","unstructured":"Baek IH, Lee BY, Lee ES, Kwon KI. Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration. Drug Res. 2013;63(07):357\u201361. https:\/\/doi.org\/10.1055\/s-0033-1341424.","journal-title":"Drug Res"},{"issue":"12","key":"1471_CR46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2165\/00003088-200544120-00011","volume":"44","author":"K Yoshihara","year":"2005","unstructured":"Yoshihara K, Gao Y, Shiga H, Wada DR, Hisaoka M. Population pharmacokinetics of olmesartan following oral administration of its prodrug olmesartan medoxomil. Clin Pharmacokinet. 2005;44(12):1329\u201342. https:\/\/doi.org\/10.2165\/00003088-200544120-00011.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1471_CR47","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1152\/physrev.00027.2008","volume":"89","author":"B Vollmar","year":"2009","unstructured":"Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev. 2009;89(4):1269\u2013339. https:\/\/doi.org\/10.1152\/physrev.00027.2008.","journal-title":"Physiol Rev"},{"issue":"9","key":"1471_CR48","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/CIRCULATIONAHA.107.763730","volume":"118","author":"BI Levy","year":"2008","unstructured":"Levy BI, Schiffrin EL, Mourad J-J, Agostini D, Vicaut E, Safar ME, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118(9):968\u201376. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.763730.","journal-title":"Circulation"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01471-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:47:43Z","timestamp":1738255663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01471-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01471-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"23 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In Hwan Jeong, Sooyoon Ryu, Nayoung Han, Christine E. Staatz, and In-hwan Baek declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. NRF-2022R1F1A1063144).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"As this is a secondary literature-based study, ethic approval is not necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"The model code that supports the findings of this study is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: In-hwan Baek; Data curation: In Hwan Jeong, Sooyoon Ryu, In-hwan Baek; Formal analysis In Hwan Jeong, Sooyoon Ryu; Funding acquisition: In-hwan Baek; Investigation: In Hwan Jeong, Nayoung Han, Christine E. Staatz, In-hwan Baek; Methodology: In Hwan Jeong, In-hwan Baek; Software: Nayoung Han, Christine E. Staatz, In-hwan Baek; Supervision: Nayoung Han, Christine E. Staatz; Validation: Nayoung Han, In-hwan Baek; Writing \u2013 original draft: In-hwan Baek; Writing \u2013 review & editing: Nayoung Han, Christine E. Staatz.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}